Thermo Fisher Scientific is divesting its microbiology business, a unit that supplies antimicrobial susceptibility testing and culture media, to private‑equity firm Astorg for $1.075 billion.

The sale follows the unit’s 2025 revenue of $645 million, which sits within Thermo Fisher’s specialty diagnostics segment. Astorg will acquire the entire operation, bringing its global reach to the clinical, pharmaceutical and food‑safety markets.

Deal completion is slated for the second half of 2026. The transaction allows Thermo Fisher to sharpen its focus on core life‑science platforms while giving Astorg a high‑margin, growth‑ready portfolio in a niche that continues to expand.

Investors will watch the closing closely, as the sale represents a significant shift in Thermo Fisher’s strategy and adds a robust, revenue‑generating asset to Astorg’s diagnostics footprint.